780Mg Metformin Base

Evidence Level: L5

Predicted Indications: 0

---

Table of Contents

1. 780Mg Metformin Base
2. 780MG METFORMIN BASE): Insufficient Data Quality to Complete Drug Repurposing Assessment
   1. One-Sentence Summary
   2. Quick Overview
   3. Why is This Prediction Reasonable?
   4. Clinical Trial Evidence
   5. Literature Evidence
   6. Singapore Market Information
   7. Safety Considerations
   8. Conclusion and Next Steps
   9. Disclaimer

---

## Pharmacist Assessment Report

780MG METFORMIN BASE): Insufficient Data Quality to Complete Drug Repurposing Assessment

⚠️ Notice: This report cannot be completed in standard format due to severe data quality issues with the input data. The following is an analysis of data gaps and recommended actions.

---

One-Sentence Summary

The drug field (INN) in this Evidence Pack contains a non-standard string "780MG METFORMIN BASE)", which appears to result from a parsing error where dosage specifications were inadvertently mixed into the drug name field, rather than representing a correct international nonproprietary name. Due to failed drug identification, the system was unable to retrieve any TxGNN predicted indications, Singapore market availability data, or safety data. At present, drug repurposing assessment cannot be executed.

---

Quick Overview

Item	Content
Input Drug Name (Raw)	780MG METFORMIN BASE) ← suspected parsing error
Presumed Correct Drug	Metformin (Metformin HCl, biguanide antidiabetic)
Predicted New Indications	None (predicted_indications array is empty)
TxGNN Prediction Score	No data
Evidence Level	L5 (model prediction data missing)
Singapore Market Status	Not marketed (0 approvals)
License Count	0
Recommended Decision	Hold

---

Why is This Prediction Reasonable?

Due to the empty predicted_indications array, mechanistic relevance analysis cannot be performed in this section.

Should the drug be confirmed as Metformin, its mechanism of action (AMPK activation, hepatic gluconeogenesis inhibition) possesses a rich research foundation in the drug repurposing field (cancer, PCOS, NAFLD, neurodegenerative disease, etc.), and would merit evaluation. However, until the drug identification issue is resolved, no prediction interpretation should be undertaken.

---

Clinical Trial Evidence

No relevant clinical trial data are currently available (predicted_indications is empty, precluding queries).

---

Literature Evidence

No relevant literature data are currently available (predicted_indications is empty, precluding queries).

---

Singapore Market Information

The present query retrieved no Singapore approval records (total_licenses: 0).

Should drug identification be confirmed as Metformin, re-querying is warranted—Metformin is widely marketed in Singapore and would be expected to have multiple HSA approval records.

---

Safety Considerations

Please consult product labeling warnings and contraindications. Safety data queries failed to return results, possibly due to failed drug identification.

---

Conclusion and Next Steps

Decision: Hold

Rationale: The drug identification field (INN) contains a malformed string, resulting in complete failure of DrugBank mapping, TxGNN prediction, Singapore market availability query, and safety assessment. Without data correction, this case presents no evaluable prediction evidence.

To proceed, the following is needed:

1. Resolve drug identification issue (Blocking)
   • Confirm correct INN: if Metformin, input should be metformin (lowercase, no parentheses, no dosage specifications)
   • Re-trigger Evidence Pack generation workflow
2. Supplement DrugBank ID (High)
   • Metformin DrugBank ID is DB00331
   • Supplementation enables retrieval of complete MOA, drug classification, and safety data
3. Re-execute TxGNN prediction
   • Upon confirmation of drug identification, regenerate predicted_indications
4. Supplement Singapore HSA data (High)
   • Metformin should have market records in Singapore; re-query to confirm
5. Supplement product labeling safety data (Blocking)
   • Per DG001 remediation measures: download product labeling PDF for parsing of warnings and contraindications

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---